Macugen

DRUG5 trials

Sponsors

Pfizer, Greater Houston Retina Research

Conditions

Macular DegenerationMacular Edema Associated With Diabetes MellitusNeovascular Age-related Macular DegenerationProliferative Diabetic Retinopathy

Phase 2

A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.

CompletedNCT00605280

PfizerMacular Edema Associated With Diabetes Mellitus

Start: 2005-09-30End: 2011-07-31Updated: 2018-11-16

Phase 3

A Study of the Safety, Tolerability, and Efficacy of IVT Pre-op 0.3mg Pegaptanib Sodium Versus Sham, for Management of Tractional Retinal Detachment and Vitreous Hemorrhage With Proliferative Diabetic Retinopathy

WithdrawnNCT01589718

Greater Houston Retina ResearchProliferative Diabetic Retinopathy

Start: 2012-04-30End: 2014-03-31Updated: 2014-03-05

Unknown Phase

Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration

CompletedNCT00460408

PfizerMacular Degeneration

Start: 2006-08-31End: 2012-02-29Updated: 2012-12-11

A Study On The Efficacy Of Macugen Injections In Patients With Neovascular Age-Related Macular Degeneration In Real Life.

CompletedNCT00549055

PfizerNeovascular Age-related Macular Degeneration

Start: 2007-11-30End: 2009-10-31Updated: 2018-12-06

Efficacy, Safety, Tolerability of Pegaptanib Sodium (Macugen) in Filipino Patients With Neovascular Age Related Macular Degeneration.

WithdrawnNCT00820742

PfizerNeovascular Age-related Macular Degeneration

Start: 2008-02-29End: 2009-05-31Updated: 2015-03-05

Related Papers

Changes in vision- and health-related quality of life in patients with diabetic macular edema treated with pegaptanib sodium or sham.

2011-09-2925 citations